Used in pharmaceutical research as a potent and selective inhibitor of anaplastic lymphoma kinase (ALK). It shows promising activity against ALK-driven cancers, particularly non-small cell lung cancer (NSCLC) with ALK gene rearrangements. The compound effectively crosses the blood-brain barrier, making it valuable in treating brain metastases associated with ALK-positive tumors. Its high selectivity reduces off-target effects, improving therapeutic efficacy and patient tolerance in clinical settings.